title: From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
authors.forename: Dimitrios H
authors.initials: DH
authors.lastname: Roukos
authors.forename: Costas
authors.initials: C
authors.lastname: Papaloukas
authors.forename: Margaret
authors.initials: M
authors.lastname: Tzaphlidou
mesh_terms: D023281:Genomics; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases; D020929:Mitogen-Activated Protein Kinase Kinases